ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $12.13M rose 42.9% year over year, ahead of the +26.0% change in trailing-twelve-month revenue. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at +21.6% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $48.5M (+31.2%) for the fiscal year ending Dec 2026, a step up from the +17.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.13M+16.5% QoQ
Last fiscal yearDec 2025
$36.97M+17.8% YoY
LTMMar 2026
$40.61M+26.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.9%+38.2%-4.8 pp
1 year+17.8%+31.2%+13.4 pp
3-year CAGR+21.6%+20.3%-1.3 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
36.97M USD
Year-over-year change
+17.8%
4-year CAGR
+22.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +26.0% is the highest of 9, against a peer median of +3.6%.
  • Over three fiscal years its annual growth of +21.6% compares with a peer median of +4.0%.
CLPT Competitors
Revenue for CLPT and competitors
Company Period LTM YoY 3-year CAGR
SNDLSNDL Inc.LTM Mar 2026CA$937.39M CAD+1.1%+9.9%
VREXVarex Imaging CorporationLTM Apr 2026$857.5M USD+3.6%-0.6%
OFIXOrthofix Medical Inc.LTM Mar 2026$825.37M USD+2.6%+21.3%
AVNSAvanos Medical, Inc.LTM Mar 2026$715.9M USD+3.9%+0.8%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$232.4M USD+25.7%-6.9%
SIBNSI-BONE, Inc.LTM Mar 2026$206.22M USD+16.8%+23.6%
CTKBCytek Biosciences, Inc.LTM Mar 2026$204.17M USD+3.6%+7.1%
LABStandard BioTools Inc.LTM Mar 2026$86.26M USD-35.8%-4.5%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$40.61M USD+26.0%+21.6%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD——
Peer median (excluding CLPT) —+3.6%+4.0%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.3M20.55M23.96M31.39M36.97M
Cost of Revenue5.18M7.02M10.34M12.27M14.28M
Gross Profit11.12M13.53M13.61M19.12M22.69M
Gross Margin68.2%65.8%56.8%60.9%61.4%
Research & Development9.28M10.89M11.71M12.39M13.9M
Selling, General & Admin15.22M18.97M24.35M26.48M32.96M
Operating Expenses24.5M29.86M36.06M38.87M46.86M
Depreciation & Amortization692K777K1.46M1.9M2.24M
EBITDA(12.75M)(15.58M)(20.63M)(17.01M)(20.86M)
EBITDA Margin-78.2%-75.8%-86.1%-54.2%-56.4%
Operating Income(13.37M)(16.33M)(22.45M)(19.75M)(24.16M)
Operating Margin-82.1%-79.5%-93.7%-62.9%-65.4%
Interest Income00386K872K1.21M
Interest Expense973K81K002.39M
Other Income / Expenses(1.04M)(103K)357K832K(1.32M)
Income Before Tax(14.41M)(16.44M)(22.09M)(18.91M)(25.49M)
Pre-Tax Margin-88.4%-80.0%-92.2%-60.3%-68.9%
Income Tax Expense000055K
Net Income(14.41M)(16.44M)(22.09M)(18.91M)(25.54M)
Net Margin-88.4%-80.0%-92.2%-60.3%-69.1%
EPS (Basic)(0.69)(0.68)(0.90)(0.70)(0.90)
EPS (Diluted)(0.69)(0.68)(0.90)(0.70)(0.90)
Weighted Avg Shares20.73M24.18M24.61M27.03M28.32M
Weighted Avg Shares (Diluted)20.73M24.18M24.61M27.03M28.32M

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.